Effects and Efficacy of Wenyang Huayin Yangxin Prescription on the Traditional Chinese Medicine Syndromes of Patients With Chronic Heart Failure Combined With Diuretic Resistance
Abstract
To study the traditional Chinese medicine (TCM) syndromes of patients with chronic heart failure (CHF) combined with diuretic resistance by using the Wenyang Huayin Yangxin Prescription, and to observe its therapeutic efficacy.
Methods A total of 68 CHF patients complicated with diuretic resistance and who had Yangqi deficiency and presenting blood stasis syndrome combined with Tanyin were randomly assigned to a control group and an observation group. The control group was given intravenous furosemide (≥ 80 mg/d) via infusion pump in addition to standard Western medical treatment, while the observation group was given intravenous furosemide (< 80 mg/d) via infusion pump along with the Wenyang Huayin Yangxin Prescription (30 g Astragalus, 15 g Poria, 15 g Baizhu, 15 g Chuanxiong, 10 g Danfu tablet, 10 g Cassia, 10 g Alisma, and 10 g Zhimu). The quantitative index of diuretic resistance was used as the primary outcome measure. In addition, the differences between the two groups in TCM syndromes, cardiac function-related indicators, incidence of endpoint events, and readmission rate were compared.
Results After 2 weeks of treatment, the filtration sodium excretion fraction (FENa) in the observation group was (0.18 ± 0.04)%, while that of the control group was (0.16 ± 0.03)%, showing a statistically significant difference (P = 0.037). The 24-hour urine volume and urine Na+/K+ ratio in the observation group increased significantly from baseline levels and were higher than those in the control group (P < 0.05). The differences in the changes of 24-hour urine volume, urine sodium, FENa, and urine Na+/K+ ratio between the two groups were statistically significant (P < 0.05). The TCM syndrome scores decreased in both groups after 2 weeks of treatment, with the observation group showing a significantly greater reduction compared with the control group (P < 0.001). The differences in the changes of TCM syndrome scores between the two groups were statistically significant (P < 0.001). After 2 weeks of treatment, the observation group showed significant improvements in palpitations, shortness of breath, facial and limb edema, spontaneous sweating, chest tightness (pain), asthma, and oliguria compared with the baseline data (P < 0.05), while the control group showed improvements only in facial and limb edema, asthma, and oliguria (P < 0.05). Except for the asthma syndrome after 2 weeks of treatment, the observation group showed better outcomes in spontaneous sweating, chest tightness (pain), asthma, and oliguria at various time points after treatment compared with the control group (P < 0.05). After 2 weeks of treatment, the observation group had significantly better cardiac output (CO) and stroke volume (SV) compared with those of the control group (P < 0.05). The differences in the changes in N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), SV, and CO between the two groups were statistically significant (P < 0.05). After 24 weeks of follow-up, no significant differences in the incidence of end-point events or readmission rates between the two groups were observed.
Conclusion The Wenyang Huayin Yangxin Prescription, combined with low-dose intravenous furosemide administered through an infusion pump, can improve the TCM syndromes of patients with Yangqi deficiency and blood stasis syndrome combined with Tanyin in addition to CHF complicated by diuretic resistance. This treatment improves the patients' heart function and diuretic resistance, reduces the intravenous dosage of diuretic, and enhances clinical efficacy. This approach should be more widely applied in clinical settings.
Keywords: Wenyang Huayin Yangxin Prescription, Diuretic resistance, TCM syndrome, Efficacy observation
Full Text:
PDFReferences
LIN M, ZHAN J, LUAN Y, et al. Development and validation of a risk score in Chinese patients with chronic heart failure. Front Cardiovasc Med, 2022, 9: 865843. doi: 10.3389/fcvm.2022.865843.
WILCOX C S, TESTANI J M, PITT B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension, 2020, 76(4): 1045-1054. doi: 10.1161/HYPER TENSIONAHA.120.15205.
TRULLAS J C, CASADO J. Diuretic resistance in heart failure. Med Clin (Barc), 2024, 162(1): 19-21. doi: 10.1016/j.medcli.2023.10.001.
Electrophysiology and Cardiac Function Branch of Chinese Society of Geriatrics, Cardiovascular Medicine Branch of Chinese Physicians Association, Expert Committee of China Heart Failure Center. Chinese expert consensus on comprehensive management of patients with worsening heart failure 2022. Chin Circ J, 2022, 37(3): 215-225. doi: 10. 3969/j.issn.1000-3614.2022.03.003.
SHAMS E, BONNICE S, MAYROVITZ H N. Diuretic resistance associated with heart failure. Cureus, 2022, 14(1): e21369. doi: 10.7759/cureus.21369.
OYAMA M A, ADIN D. Toward quantification of loop diuretic responsiveness for congestive heart failure. J Vet Intern Med, 2023, 37(1): 12-21. doi: 10.1111/jvim.16590.
DONG G J, LIU Y C. Expert consensus on Qi-deficiency, blood stasis and water-drinking syndrome of heart failure based on the preservation of ejection fraction combined with traditional Chinese and western medicine. Chin Arch Tradit Chin Med, 2023, 41(7): 255-258. doi: 10. 13193/j.issn.1673-7717.2023.07.051.
Chinese Society of Cardiology. Chinese guidelines for diagnosis and treatment of heart failure 2018. Chin J Cardiol, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004.
FELKER G M, ELLISON D H, MULLENS W, et al. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol, 2020, 75(10): 1178-1195. doi: 10.1016/j.jacc.2019.12.059.
Cardiovascular Disease Professional Committee of the Chinese Society of Integrated Traditional Chinese and Western Medicine, Cardiovascular Disease Expert Committee of the Integrated Traditional Chinese and Western Medicine Physician Branch of the Chinese Medical Association. Expert consensus on the diagnosis and treatment of chronic heart failure by integrated Chinese and Western medicine. Chin J Integr Med Cardio/Cerebrovasc Dis, 2016, 14(3): 225-232. doi: 10.3969/j.issn.1672-1349.2016.03.001.
ZHEN X Y. Guiding principles of clinical research on new Chinese medicine (trial). Beijing: China Medical Science and Technology Press, 2002: 77-85.
Chinese College of Cardiovascular Physicians, Electrocardiology and Cardiac Function Branch of Chinese Geriatric Society, Alliance Expert Committee of China Heart Failure Center. Chinese expert consensus for the diagnosis and management of diuretic resistance in patients with heart failure. J Clin Cardiol, 2024, 40(4): 257-267. doi: 10.13201/j.issn. 1001-1439.2024.04.002.
LI Z H, LI R N, YE Z, et al. Pathogenesis and treatment of diuretic resistance in patients with heart failure. Adv Cardiovasc Dis, 2024, 45(8): 717-721. doi: 10.16806/j.cnki.issn.1004-3934.2024.08.010.
COX Z L, RAO V S, TESTANI J M. Classic and novel mechanisms of diuretic resistance in cardiorenal syndrome. Kidney360, 2022, 3(5): 954-967. doi: 10.34067/KID.0006372021.
GOMES Da SIVLA F, CALCA R, RITA M A, et al. Diuretic-resistant heart failure and the role of ultrafiltration: a proposed protocol. Rev Port Cardiol, 2023, 42(9): 797-803. doi: 10.1016/j.repc.2022.05.012. ELLISON D H. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol, 2019, 14(8): 1248-1257. doi: 10.2215/CJN.09630818.
SHAH N, MADANIEH R, KAN M A, et al. A perspective on diuretic resistance in chronic congestive heart failure. Ther Adv Cardiovasc Dis, 2017, 11(10): 217-278. doi: 10.1177/1753944717718717.
ADIN D, ATKINS C, WALLACE G, et al. Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs. J Vet Intern Med, 2021, 35(3): 1245-1254. doi: 10.1111/jvim.16097.
Refbacks
- There are currently no refbacks.



